Patents Assigned to Bristol-Myers Squibbs Company
-
Publication number: 20240190963Abstract: The disclosure provides a method for treating a subject afflicted with a tumor derived from a non-small cell lung cancer (NSCLC) comprising administering to the subject a therapeutically effective amount of (a) an anti-PD-1 antibody or antigen-binding portion thereof or an anti-PD-L1 antibody or antigen-binding portion thereof and (b) an anti-CTLA-4 antibody or an antigen binding portion thereof, wherein the tumor has a high tumor mutation burden (TMB) status. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.Type: ApplicationFiled: September 15, 2023Publication date: June 13, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Prabhu Seshaiyer Bhagavatheeswaran, Nicholas Allan John Botwood, Han Chang, Yali Fu, William J. Geese, George A. Green, IV, Diane Healey, Sabine Maier, Faith E. Nathan, Abderrahim Oukessou, Giovanni Selvaggi, Joseph Daniel Szustakowski
-
Publication number: 20240185972Abstract: A method includes receiving input data including unstructured text representing one or more sequences of terms. For each respective sequence of terms, the method includes generating a corresponding line of therapy (LoT) pseudo-label indicating whether the respective sequence of terms includes LoT information, generating a corresponding LoT indicator predicting whether the respective sequence of terms includes LoT information, and determining a corresponding LoT indication loss based on the corresponding LoT pseudo-label and the corresponding LoT indicator. The method also includes fine-tuning a pre-trained transformer model based on the LoT indication losses determined for the one or more sequences of terms.Type: ApplicationFiled: December 1, 2023Publication date: June 6, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Sazedul Alam, Gengyuan Liu, Devansh Agarwal, Md Shamsuzzaman
-
Publication number: 20240180886Abstract: Disclosed are compounds of Formula (I) pharmaceutically acceptable salts thereof are defined herein, and pharmaceutical compositions thereof and combinations thereof, and methods of using the same as inhibitors of protein tyrosine phosphatases (PTPN2). These compounds are useful in treating cancer and diseases susceptible to PTPN2 inhibition.Type: ApplicationFiled: November 8, 2023Publication date: June 6, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: YUCHENG MU, HAIBO LIU, ANNAPURNA PENDRI, SHOSHANA L. POSY, JOANNE JEWETT BRONSON, LAURA AKULLIAN D'AGOSTINO
-
Patent number: 11998537Abstract: Disclosed are compounds of Formula (I) Formula (I) N-oxides, or salts thereof, wherein G1, G2, L, R1a, R1b, R4, R5, n, m, x, and y are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: October 22, 2019Date of Patent: June 4, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Brian K. Whiteley, John L. Gilmore
-
Publication number: 20240174749Abstract: This disclosure provides a method for treating a subject afflicted with a tumor or a cancer, wherein the method comprises administering to the subject therapeutically effective amounts of an anti-TIM3 antibody, alone or in combination with an inhibitor of the PD-1 signaling pathway (e.g., anti-PD-1 antibody). In some embodiments, the antibody is administered as a flat dose or a weight-based dose.Type: ApplicationFiled: September 27, 2023Publication date: May 30, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Xiao Min SCHEBYE, Mark J. SELBY, Michelle Minhua HAN, Christine BEE, Andy X. DENG, Anan CHUNTHARAPAI, Brigitte DEVAUX, Huiming LI, Paul O. SHEPPARD, Alan J. KORMAN, Daniel F. ARDOUREL, Ekaterina DEYANOVA, Richard Yu-Cheng HUANG, Guodong CHEN, Michelle Renne KUHNE, Hong-An TRUONG, Poliana PATAH, Jeffrey R. JACKSON, Ronald A. FLEMING
-
Patent number: 11981680Abstract: The present invention provides compounds of formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.Type: GrantFiled: August 7, 2019Date of Patent: May 14, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Daniel S. Gardner, John V. Duncia, Joseph B. Santella
-
Patent number: 11981734Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.Type: GrantFiled: February 10, 2022Date of Patent: May 14, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Natalie Bezman, Alan J. Korman, Shrikant Deshpande, Amy D. Jhatakia, Richard Y. Huang, Guodong Chen, Ginger C. Rakestraw, Karla Ann Henning, Vangipuram S. Rangan, Christine Bee, Xiang Shao
-
Patent number: 11970511Abstract: The present disclosure relates to compounds of Formula (1), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods making and using such compounds and compositions.Type: GrantFiled: June 13, 2019Date of Patent: April 30, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Richard A. Hartz, Li Xu, David S. Yoon, Alicia Regueiro-Ren, Prasada Rao Jalagam, Manoranjan Panda, Satheesh Kesavan Nair
-
Publication number: 20240132622Abstract: The present application relates to particular anti-PAD4 (peptidyl arginine deiminase 4) antibodies, nucleic acids encoding the antibodies, vectors and host cells comprising the nucleic acids, and methods of making and using the antibodies.Type: ApplicationFiled: July 20, 2023Publication date: April 25, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Lin Hui Su, Ekaterina Deyanova, Burce Ergel Gurbuzbalaban, Mariana Nacht, Samantha Elaine Pace, Yun Wang, Qing Xiao, Ramakrishna Chandran, Shailesh Dudhgaonkar, Michael Louis Doyle, Michael Gilman, Richard Huang, Akbar Nayeem, Alok Sharma, Qihong Zhao
-
Patent number: 11964973Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR6 or N; Y is CR3 or N; R1, R2, R3, R4, R5, R6, R7, and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGK?) and diacylglycerol kinase zeta (DGK?), and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.Type: GrantFiled: December 22, 2020Date of Patent: April 23, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Robert G. Gentles, Upender Velaparthi, Min Ding, Richard E. Olson, Scott W. Martin, Saumya Roy, Prasada Rao Jalagam, Jayakumar Sankara Warrier, Louis S. Chupak, Denise Christine Grunenfelder
-
Patent number: 11965031Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.Type: GrantFiled: November 16, 2020Date of Patent: April 23, 2024Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
-
Publication number: 20240124589Abstract: This disclosure provides a method for treating a subject afflicted with a urothelial carcinoma or cancer derived therefrom, which method comprises administering to the subject an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity or the combination of (a) an antibody or an antigen-binding portion thereof that specifically binds to a PD-1 receptor and inhibits PD-1 activity; and (b) an antibody or an antigen-binding portion thereof that specifically binds to a Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) and inhibits CTLA-4 activity.Type: ApplicationFiled: September 25, 2023Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventor: Marina TSCHAIKA
-
Publication number: 20240124597Abstract: The disclosure provides for antibodies that bind CD40, including a humanized antibody. The antibodies bind CD40 and do not exhibit CD40 agonist activity. The antibodies may comprise a modified IgG1 Fc domain, and exhibit minimal activation of immature dendritic cells. Compositions comprising antibodies, methods of use for treatment of diseases involving CD40 activity, and use in the preparation of a medicament for treatment of a disease involving CD40 activity are provided.Type: ApplicationFiled: August 22, 2023Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Aaron YAMNIUK, Mary STRUTHERS, Stanley R. KRYSTEK, JR., Akbar NAYEEM, Ginger RAKESTRAW
-
Publication number: 20240124592Abstract: This disclosure provides a method for treating HPV-positive squamous cell carcinoma of the head and neck comprising administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The disclosure also provides a method for treating HPV-negative squamous cell carcinoma of the head and neck administering to the subject an immune checkpoint inhibitor, e.g., an anti-PD-1 antibody or an anti-PD-L1 antibody. The subject can be additionally administered another anti-cancer agent.Type: ApplicationFiled: July 26, 2023Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Demetrios MANEKAS, Joseph GROSSO, Jeffrey A. ANDERSON
-
Publication number: 20240124417Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.Type: ApplicationFiled: October 1, 2020Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Kap-Sun YEUNG, Denis R. ST. LAURENT, Li-Qiang SUN, Zhiwei YIN, Katharine A. GRANT-YOUNG, Paul Michael SCOLA
-
Publication number: 20240127451Abstract: Described herein are methods and computer systems for classification of CD8 T-cell topology using a patient response-based linear cutoff model. A plurality of histology images of tissue samples in a plurality of patients are received by a computer system. An image analysis of the plurality of histology images is performed to obtain a CD8+ T-cell abundance in the tumor parenchyma and stroma in each of the plurality of histology images. Real inflammation scores and tumor infiltration scores are determined based on a polar coordinate transformation of the CD8+ T-cell abundance in the tumor parenchyma and stroma. Based on the real inflammation scores and tumor infiltration scores, a feature space is generated, and linear boundaries or linear cutoffs between a plurality of classifications in the feature space are identified based on the real inflammation scores, the tumor infiltration scores, and patient response data.Type: ApplicationFiled: February 25, 2022Publication date: April 18, 2024Applicant: Bristol-Myers Squibb CompanyInventors: George C. Lee, Robin Edwards, Scott Ely, Daniel N. Cohen, John B. Wojcik, Vipul A. Baxi, Dimple Pandya, Jimena Trillo-Tinoco, Benjamin J. Chen, Andrew Fisher, Falon Gray
-
Publication number: 20240117044Abstract: Provided herein are methods for treating a subject afflicted with a cancer, comprising administering to the subject a TIM3 agonist (e.g., an anti-TIM3 antibody), alone or in conjunction with another immune checkpoint inhibitor (e.g., a PD-1 antagonist), wherein the subject is identified as having a high frequency of TIM3 positive cells (e.g., on the tumor infiltrating inflammatory cells) or soluble TIM3 in peripheral blood. Also provided are methods for assessing the efficacy of a treatment comprising a TIM3 antagonist in a subject afflicted with a cancer, comprising measuring the frequency of TIM3 (and optionally PD-1) positive cells in certain populations of cells and/or the soluble TIM3 in peripheral blood of the subject, wherein a high frequency of TIM3 (and optionally PD-1) positive cells and/or the subject's peripheral blood titer of soluble TIM3 is indicative of the response to the treatment.Type: ApplicationFiled: September 8, 2023Publication date: April 11, 2024Applicant: Bristol-Myers Squibb CompanyInventors: Anke KLIPPEL, Laurence Celine MENARD
-
Publication number: 20240116988Abstract: There are disclosed novel anti-ROR1 macrocyclic peptides and their conjugates with general structure of formula (I), which can be used as ROR1 inhibitors.Type: ApplicationFiled: August 23, 2023Publication date: April 11, 2024Applicant: BRISTOL-MYERS SQUIBB COMPANYInventors: JENNIFER X. QIAO, VING G. LEE, TAMMY C. WANG, MICHAEL A. POSS
-
Patent number: 11952434Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.Type: GrantFiled: April 20, 2022Date of Patent: April 9, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Paul Michael Scola, David R. Langley, Nicholas A. Meanwell
-
Patent number: RE49931Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.Type: GrantFiled: January 25, 2022Date of Patent: April 23, 2024Assignee: Bristol-Myers Squibb CompanyInventors: Alaric J. Dyckman, Dharmpal S. Dodd, Christopher P. Mussari, Laxman Pasunoori, Sreekantha Ratna Kumar